A two drug combo for viral reduction makes little sense for CYDY. It would be more expensive than monotherapy (unless we take a hit on revenue). I don't think it will improve much on efficacy over monotherapy alone. Then there's the side effects brought over from the other drug.

For another pharmaceutical company it makes sense, if we shelve the monotherapy trial. With a two drug combo they make revenue and their drug doesn't become obsolete.